News & Events about Neogenomics Inc.
Needham & Company LLC restated their buy rating on shares of NeoGenomics (NASDAQ:NEO Get Rating) in a research report report published on Wednesday morning, Benzinga reports. They currently have a $21.00 target price on the medical research companys stock. Other research analysts have also recently ...
Massive Bio, Inc., a private AI-enabled oncology startup that provides virtual and in-person concierge services for cancer patients, and NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced a...
FT MYERS, FL / ACCESSWIRE / March 16, 2023 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology testing and global contract research services, announced today the commercial availability of the RaDaR® assay, a liquid biopsy test for molecular/minimal residual disease (MRD). MRD...
NeoGenomics (NASDAQ:NEO Get Rating) and BioNano Genomics, Inc. WT EXP 082123 (NASDAQ:BNGOW Get Rating) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ...
NeoGenomics (NASDAQ:NEO Get Rating) and BioNano Genomics, Inc. WT EXP 082123 (NASDAQ:BNGOW Get Rating) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, ...